Results 241 to 250 of about 355,663 (359)

Super‐Enhancer Target Gene CBP/p300‐Interacting Transactivator With Glu/Asp‐Rich C‐Terminal Domain, 2 Cooperates With Transcription Factor Forkhead Box J3 to Inhibit Pulmonary Vascular Remodeling

open access: yesCell Proliferation, EarlyView.
During hypoxia, the transcriptional effect of super‐enhancer in promoting CBP/p300‐interacting transactivator with Glu/Asp‐rich C‐terminal domain, 2 reduced, eventually leading to the thickening of the smooth muscle layer of the pulmonary artery.
Songyue Li   +11 more
wiley   +1 more source

A Rare Case of Fungal Granuloma Confined to the Nasal Septum. [PDF]

open access: yesCureus
Tamura K   +4 more
europepmc   +1 more source

Surgical technique for reconstruction of the nasal septum: The pericranial flap [PDF]

open access: bronze, 2000
Vicente Paloma   +2 more
openalex   +1 more source

Assessment of Nasal Septum Change after Le Fort I Osteotomy Using Cone Beam Computed Tomography. [PDF]

open access: yesJ Maxillofac Oral Surg, 2023
Rattana-Arpha P   +3 more
europepmc   +1 more source

Mucosal infection with Tsukamurella species following nasal septum procedure: a rare case report. [PDF]

open access: yesAnn Med Surg (Lond)
Sidhu AK   +4 more
europepmc   +1 more source

Low Grade Chondrosarcoma of the Posterior Nasal Septum. [PDF]

open access: yesIndian J Otolaryngol Head Neck Surg, 2023
Dikici O, Durgut O.
europepmc   +1 more source

Endoscopic View of a Hematoma of the Nasal Septum [PDF]

open access: bronze, 2000
Eiji Yanagisawa, Jason R. Klenoff
openalex   +1 more source

Pneumocystis jirovecii pneumonia–Immune reconstitution inflammatory syndrome: A review of published cases

open access: yesHIV Medicine, EarlyView.
Abstract Background Immune reconstitution inflammatory syndrome (IRIS) can occur in patients with HIV after commencing antiretroviral therapy. Tuberculosis–IRIS is the most common, and Pneumocystis jirovecii pneumonia (PJP)–IRIS accounts for only 2.7%–4% of IRIS cases.
Natasha Marcella Vaselli   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy